Furthermore, subgroup analysis of the EMBRACE-HF reported that SGLT-2 inhibitors reduced pulmonary artery diastolic pressure similarly for HFpEF patients with AF and those without AF [35]. This evidence concerns the gene SLC5A2 and atrial fibrillation.